Latest Advancements in CAR-T Therapy with Dr. Ehsan Malek
Listen to this pre-recorded podcast to learn from Dr. Ehsan Malek, a hematologist oncologist at Roswell Park, about some of the major breakthroughs in CAR T therapy in 2024 and what is on the horizon in 2025.
29 Aug 2024
Research Advancements for HIV-associated Diffuse Large B-cell Lymphoma
Dr. Kathryn Lurain shares about the advancements in HIV-associated DLBCL treatment, covering research, challenges, and future directions.
3 May 2024
DLBCL and Follicular Lymphoma Clinical Trials at MD Anderson
Dr. Strati shares about trials happening at MD Anderson for DLBCL and follicular lymphoma. This includes the following:
Two completed follicular lymphoma trials:
Phase I study of evorpacept and R2 in relapsed indolent B-NHL
Phase 2 study of acalabrutinib and R2 in previously untreated indolent B-NHL
One ongoing DLBCL trial:
Phase 2 study of loncastuximab as consolidation after CART in DLBCL
One upcoming DLBCL trial:
Phase 2 study of emapalaumab for the treatment of persistent severe cytopenia after CART in DLBCL
11 Apr 2024
Targeted Therapy Combinations: VVIP, VIPOR, and VIPOR-P Clinical Trials
Dr. Melani discusses the latest updates from the VVIP, VIPOR, and VIPOR-P studies, which are clinical trials for non-Hodgkin's lymphoma. The goal of these studies is to improve the outcome for patients with relapsed or refractory lymphomas by using targeted therapy combinations. The targeted therapies block specific proteins that cancer cells need to grow and survive. The conversation also discusses these three clinical trials' design and treatment protocols.
1 Mar 2024
PET Biomarkers in Lymphoma with Dr. Juan Pablo Alderuccio
Defining and tracking progression/remission in DLBCL patients can be subjective and complicated. In this episode, we are joined by Dr. Juan Pablo Alderuccio, a lymphoma specialist at the University of Miami. Dr. Alderuccio recently published his research (https://pubmed.ncbi.nlm.nih.gov/37460635/) on PET-based biomarkers in lymphoma patients. His research aims to give patients a more accurate knowledge of their lymphoma prognosis.
Thank you to our episode sponsor, Regeneron.
Podcast Authority Score: 1 / 100
A composite of feed quality, social presence, YouTube performance and engagement. Read the methodology.
Quality
1
Social presence
0
YouTube
0
Engagement
0
Contact HealthTree Podcast for DLBCL
Guest appearances
Does not typically book guests
Based on episode analysis; this does not confirm that the show is currently accepting guests.
Host of HealthTree Podcast for DLBCL?
Claim your podcast to manage its listing and keep your show details accurate.
Pod Engine is an independent podcast discovery and analytics service and is not affiliated with or endorsed by this podcast. Artwork and show content belong to their owners. Full legal notice.
Explore this show Podcast research with Pod Engine
